Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for Timothy P Clackson. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at Timothy P Clackson har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:ELEV / Elevation Oncology, Inc. | Director | 0 |
US: / THESEUS PHARMACEUTICALS INC | President and CEO, Director | 351 030 |
US:FMTX / Forma Therapeutics Holdings Inc | Director | 0 |
US:XLO / Xilio Therapeutics, Inc. | 10% Owner | 20 068 |
US:849CVR014 / CVR F STAR | Director | 50 486 |
US:ARIA / ARIAD Pharmaceuticals, Inc. | President, R&D, CSO | 0 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av Timothy P Clackson. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Internkjøp XLO / Xilio Therapeutics, Inc. - Analyse av kortsiktig fortjeneste
I denne seksjonen analyserer vi lønnsomheten av hvert uplanlagt, åpen-marked internsalg som er gjort i XLO / Xilio Therapeutics, Inc.. Denne analysen hjelper til å forstå om den interne personen regelmessig genererer unormale avkastninger, og er verdt å følge. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til maks |
Pris ved maks |
Maks fortjeneste ($) |
Maks fortjeneste (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internhandel XLO / Xilio Therapeutics, Inc. - Analyse av kortsiktig tap
I denne seksjonen analyserer vi unngåelsen av kortsiktig tap for hvert uplanlagt, åpen-marked internsalg som er gjort i XLO / Xilio Therapeutics, Inc.. Et jevnt mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til min |
Pris ved min |
Maks tap unngått ($) |
Maks tap unngått (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av Timothy P Clackson som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-07-24 |
|
4 | ELEV |
Elevation Oncology, Inc.
Common Stock |
U - Other | −47 330 | 0 | −100,00 | 0,36 | −17 039 | ||
2023-09-05 |
|
4 | ELEV |
Elevation Oncology, Inc.
Common Stock |
G - Gift | −15 777 | 0 | −100,00 | ||||
2022-11-14 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 2 500 | 351 030 | 0,72 | 6,80 | 16 995 | 2 386 302 | |
2022-10-14 |
|
4 | FMTX |
Forma Therapeutics Holdings, Inc.
Common Stock |
U - Other | −7 250 | 0 | −100,00 | ||||
2022-10-14 |
|
4 | FMTX |
Forma Therapeutics Holdings, Inc.
Common Stock |
U - Other | −23 590 | 0 | −100,00 | ||||
2022-06-22 |
|
4 | ELEV |
Elevation Oncology, Inc.
Common Stock |
G - Gift | −31 553 | 15 777 | −66,67 | ||||
2022-06-09 |
|
4 | FMTX |
Forma Therapeutics Holdings, Inc.
Common Stock |
A - Award | 4 500 | 30 840 | 17,08 | ||||
2022-02-23 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Stock Option (right to buy) |
A - Award | 450 000 | 450 000 | |||||
2021-12-22 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 2 600 | 348 530 | 0,75 | 9,76 | 25 381 | 3 402 385 | |
2021-10-21 | 3 | XLO |
Xilio Therapeutics, Inc.
Common Stock |
20 068 | ||||||||
2021-10-21 | 3 | XLO |
Xilio Therapeutics, Inc.
Common Stock |
70 888 | ||||||||
2021-10-06 | 3 | THRX |
Theseus Pharmaceuticals, Inc.
Common Stock |
345 930 | ||||||||
2021-06-24 | 3 | ELEV |
Elevation Oncology, Inc.
Common Stock |
47 330 | ||||||||
2021-06-21 |
|
4 | FMTX |
Forma Therapeutics Holdings, Inc.
Stock Option (Right to Buy) |
A - Award | 8 375 | 8 375 | |||||
2021-06-21 |
|
4 | FMTX |
Forma Therapeutics Holdings, Inc.
Common Stock |
A - Award | 2 750 | 26 340 | 11,66 | ||||
2020-10-01 |
|
4 | SBPH |
Spring Bank Pharmaceuticals, Inc.
Common Stock |
A - Award | 9 422 | 50 486 | 22,94 | ||||
2020-07-01 |
|
4 | SBPH |
Spring Bank Pharmaceuticals, Inc.
Common Stock |
A - Award | 8 588 | 41 064 | 26,44 | ||||
2020-06-25 |
|
4 | SBPH |
Spring Bank Pharmaceuticals, Inc.
Stock Option (right to buy) |
A - Award | 7 500 | 7 500 | |||||
2020-06-24 |
|
4 | FMTX |
Forma Therapeutics Holdings, Inc.,
Enterprise 5 Junior Stock |
S - Sale | −35 067 | 0 | −100,00 | ||||
2020-06-24 |
|
4 | FMTX |
Forma Therapeutics Holdings, Inc.,
Common Stock |
P - Purchase | 23 590 | 23 590 | |||||
2020-06-22 |
|
4 | FMTX |
Forma Therapeutics Holdings, Inc.,
Stock Option (Right to Buy) |
A - Award | 17 533 | 0 | −100,00 | ||||
2020-06-18 | 3 | FMTX |
Forma Therapeutics Holdings, Inc.,
Enterprise 5 Junior Stock |
43 144 | ||||||||
2020-06-18 | 3 | FMTX |
Forma Therapeutics Holdings, Inc.,
Enterprise 5 Junior Stock |
43 144 | ||||||||
2020-06-18 | 3 | FMTX |
Forma Therapeutics Holdings, Inc.,
Enterprise 5 Junior Stock |
43 144 | ||||||||
2020-04-01 |
|
4 | SBPH |
Spring Bank Pharmaceuticals, Inc.
Common Stock |
A - Award | 13 575 | 32 476 | 71,82 | ||||
2020-01-02 |
|
4 | SBPH |
Spring Bank Pharmaceuticals, Inc.
Common Stock |
A - Award | 7 991 | 18 901 | 73,24 | ||||
2019-10-01 |
|
4 | SBPH |
Spring Bank Pharmaceuticals, Inc.
Common Stock |
A - Award | 3 670 | 10 910 | 50,69 | ||||
2019-07-11 |
|
4 | SBPH |
Spring Bank Pharmaceuticals, Inc.
Stock Option (right to buy) |
A - Award | 7 500 | 7 500 | |||||
2019-07-01 |
|
4 | SBPH |
Spring Bank Pharmaceuticals, Inc.
Common Stock |
A - Award | 3 421 | 7 240 | 89,58 | ||||
2019-04-02 |
|
4 | SBPH |
Spring Bank Pharmaceuticals, Inc.
Common Stock |
A - Award | 1 204 | 3 819 | 46,04 | ||||
2019-01-03 |
|
4 | SBPH |
Spring Bank Pharmaceuticals, Inc.
Common Stock |
A - Award | 1 083 | 2 615 | 70,69 | ||||
2018-10-02 |
|
4 | SBPH |
Spring Bank Pharmaceuticals, Inc.
Common Stock |
A - Award | 788 | 1 532 | 105,91 | ||||
2018-07-03 |
|
4 | SBPH |
Spring Bank Pharmaceuticals, Inc.
Common Stock |
A - Award | 744 | 744 | |||||
2018-03-05 |
|
4 | SBPH |
Spring Bank Pharmaceuticals, Inc.
Stock Option (right to buy) |
A - Award | 11 000 | 11 000 | |||||
2018-03-05 | 3 | SBPH |
Spring Bank Pharmaceuticals, Inc.
No securities are beneficially owned |
0 | ||||||||
2017-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
D - Sale to Issuer | −14 550 | 0 | −100,00 | ||||
2017-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
D - Sale to Issuer | −72 980 | 0 | −100,00 | ||||
2017-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
D - Sale to Issuer | −87 125 | 0 | −100,00 | ||||
2017-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
D - Sale to Issuer | −65 000 | 0 | −100,00 | ||||
2017-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
D - Sale to Issuer | −82 000 | 0 | −100,00 | ||||
2017-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | −577 | 0 | −100,00 | ||||
2017-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | −219 867 | 0 | −100,00 | ||||
2017-02-07 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
A - Award | 14 550 | 14 550 | |||||
2017-02-02 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −29 333 | 0 | −100,00 | ||||
2017-02-02 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
F - Taxes | −9 610 | 219 867 | −4,19 | 23,82 | −228 886 | 5 236 682 | |
2017-02-02 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 29 333 | 229 477 | 14,66 | ||||
2016-10-25 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −19 638 | 197 884 | −9,03 | 9,56 | −187 739 | 1 891 771 |
2016-09-28 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −8 750 | 217 522 | −3,87 | 13,98 | −122 311 | 3 040 610 |
2016-09-28 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Performance stock unit |
M - Exercise | −17 500 | 0 | −100,00 | ||||
2016-09-28 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 17 500 | 226 272 | 8,38 | ||||
2016-09-23 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −20 000 | 208 772 | −8,74 | 13,43 | −268 536 | 2 803 140 |
2016-09-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −59 369 | 0 | −100,00 | ||||
2016-09-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −59 369 | 228 772 | −20,60 | 11,73 | −696 398 | 2 683 496 |
2016-09-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 59 369 | 288 141 | 25,95 | 7,82 | 464 266 | 2 253 263 |
2016-08-23 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −19 436 | 228 772 | −7,83 | 10,47 | −203 538 | 2 395 746 |
2016-08-15 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −25 000 | 0 | −100,00 | ||||
2016-08-15 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −25 000 | 248 208 | −9,15 | 10,50 | −262 500 | 2 606 184 |
2016-08-15 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 25 000 | 273 208 | 10,07 | 7,69 | 192 250 | 2 100 970 |
2016-07-25 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −18 286 | 248 208 | −6,86 | 8,11 | −148 230 | 2 012 024 |
2016-07-05 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −30 000 | 0 | −100,00 | 3,25 | −97 500 | ||
2016-07-05 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −31 422 | 0 | −100,00 | 4,49 | −141 085 | ||
2016-07-05 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −30 000 | 266 494 | −10,12 | 7,48 | −224 481 | 1 994 095 |
2016-07-05 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 30 000 | 296 494 | 11,26 | 3,25 | 97 500 | 963 606 |
2016-07-05 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −31 422 | 266 494 | −10,55 | 7,48 | −235 153 | 1 994 361 |
2016-07-05 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 31 422 | 297 916 | 11,79 | 4,49 | 141 085 | 1 337 643 |
2016-06-23 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −23 999 | 264 742 | −8,31 | 7,28 | −174 638 | 1 926 501 |
2016-05-25 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −17 762 | 288 741 | −5,80 | 8,08 | −143 430 | 2 331 612 |
2016-05-02 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −11 700 | 306 503 | −3,68 | 7,13 | −83 478 | 2 186 868 |
2016-05-02 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −23 400 | 0 | −100,00 | ||||
2016-05-02 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 23 400 | 318 203 | 7,94 | ||||
2016-04-25 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −21 409 | 294 803 | −6,77 | 7,37 | −157 864 | 2 173 789 |
2016-03-23 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −23 834 | 316 212 | −7,01 | 6,58 | −156 871 | 2 081 244 |
2016-03-22 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −10 833 | 0 | −100,00 | ||||
2016-03-22 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −5 417 | 340 046 | −1,57 | 6,47 | −35 039 | 2 199 520 |
2016-03-22 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 10 833 | 345 463 | 3,24 | ||||
2016-03-09 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
A - Award | 26 180 | 26 180 | |||||
2016-03-09 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
A - Award | 87 125 | 87 125 | |||||
2016-03-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −9 625 | 334 630 | −2,80 | 6,12 | −58 867 | 2 046 631 |
2016-03-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | −25 047 | 344 255 | −6,78 | 6,00 | −150 282 | 2 065 530 | |
2016-03-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Performance stock unit |
A - Award | 38 500 | 38 500 | |||||
2016-03-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Performance stock unit |
M - Exercise | −19 250 | 19 250 | −50,00 | ||||
2016-03-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 19 250 | 369 302 | 5,50 | ||||
2016-02-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −29 333 | 29 333 | −50,00 | ||||
2016-02-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −14 667 | 350 052 | −4,02 | 4,81 | −70 517 | 1 683 015 |
2016-02-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 29 333 | 364 719 | 8,75 | ||||
2015-09-28 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −8 750 | 334 086 | −2,55 | 6,46 | −56 560 | 2 159 532 |
2015-09-28 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Performance stock unit |
A - Award | 35 000 | 35 000 | |||||
2015-09-28 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Performance stock unit |
M - Exercise | −17 500 | 17 500 | −50,00 | ||||
2015-09-28 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 17 500 | 342 836 | 5,38 | ||||
2015-07-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −7 000 | 325 336 | −2,11 | 8,54 | −59 797 | 2 779 150 |
2015-07-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Performance stock unit |
M - Exercise | −14 000 | 0 | −100,00 | ||||
2015-07-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 14 000 | 332 336 | 4,40 | ||||
2015-04-30 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
A - Award | 70 200 | 70 200 | |||||
2015-04-27 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −123 766 | 316 548 | −28,11 | 9,50 | −1 175 777 | 3 007 206 |
2015-03-23 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −13 333 | 0 | −100,00 | ||||
2015-03-23 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −6 667 | 440 314 | −1,49 | 8,55 | −57 016 | 3 765 565 |
2015-03-23 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 13 333 | 446 981 | 3,07 | ||||
2015-03-23 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −5 417 | 433 648 | −1,23 | 8,84 | −47 910 | 3 835 313 |
2015-03-23 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −20 657 | 0 | −100,00 | ||||
2015-03-23 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −10 833 | 10 833 | −50,00 | ||||
2015-03-23 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | −20 657 | 440 314 | −4,48 | 9,00 | −185 913 | 3 962 826 | |
2015-03-23 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 20 657 | 460 971 | 4,69 | 7,56 | 156 167 | 3 484 941 | |
2015-03-23 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 10 833 | 439 065 | 2,53 | ||||
2015-02-24 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −24 036 | 31 422 | −43,34 | ||||
2015-02-24 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −24 999 | 0 | −100,00 | ||||
2015-02-24 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −24 036 | 428 232 | −5,31 | 8,00 | −192 288 | 3 425 856 |
2015-02-24 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 24 036 | 452 268 | 5,61 | 4,49 | 107 922 | 2 030 683 | |
2015-02-24 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −24 999 | 428 232 | −5,52 | 8,00 | −199 992 | 3 425 856 |
2015-02-24 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 24 999 | 453 231 | 5,84 | 2,62 | 65 497 | 1 187 465 | |
2015-02-04 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −29 334 | 58 666 | −33,33 | ||||
2015-02-04 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −14 667 | 428 232 | −3,31 | 6,33 | −92 820 | 2 710 066 |
2015-02-04 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 29 334 | 442 899 | 7,09 | ||||
2014-07-17 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Performance stock unit |
M - Exercise | −14 000 | 14 000 | −50,00 | ||||
2014-07-17 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
F - Taxes | −4 564 | 413 565 | −1,09 | 5,57 | −25 421 | 2 303 557 | |
2014-07-17 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 14 000 | 418 129 | 3,46 | ||||
2014-04-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −6 500 | 403 028 | −1,59 | 8,21 | −53 337 | 3 307 127 |
2014-04-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −13 000 | 0 | −100,00 | ||||
2014-04-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 13 000 | 409 528 | 3,28 | ||||
2014-03-21 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −6 667 | 394 377 | −1,66 | 7,89 | −52 583 | 3 110 451 |
2014-03-21 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −13 333 | 13 333 | −50,00 | ||||
2014-03-21 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 13 333 | 401 044 | 3,44 | ||||
2014-03-21 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −10 834 | 21 666 | −33,34 | ||||
2014-03-21 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
F - Taxes | −3 442 | 387 711 | −0,88 | 8,19 | −28 190 | 3 175 353 | |
2014-03-21 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 10 834 | 391 153 | 2,85 | ||||
2014-02-04 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
A - Award | 88 000 | 88 000 | |||||
2013-12-20 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −9 750 | 380 319 | −2,50 | 5,14 | −50 115 | 1 954 840 |
2013-12-20 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 19 500 | 390 069 | 5,26 | ||||
2013-09-10 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −8 449 | 370 451 | −2,23 | 22,00 | −185 878 | 8 149 922 |
2013-07-18 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −14 000 | 378 900 | −3,56 | 19,79 | −277 045 | 7 498 014 |
2013-07-17 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Performance stock unit |
M - Exercise | −28 000 | 28 000 | −50,00 | ||||
2013-07-17 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Performance stock unit |
A - Award | 56 000 | 56 000 | |||||
2013-07-17 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 28 000 | 392 900 | 7,67 | ||||
2013-04-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | −6 500 | 363 705 | −1,76 | 18,04 | −117 245 | 6 560 402 | |
2013-04-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −13 000 | 0 | −100,00 | ||||
2013-04-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 13 000 | 370 205 | 3,64 | ||||
2013-03-26 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | −19 167 | 357 205 | −5,09 | 18,87 | −361 766 | 6 742 030 | |
2013-03-26 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −38 333 | 0 | −100,00 | ||||
2013-03-26 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 38 333 | 376 372 | 11,34 | ||||
2013-03-22 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | −6 667 | 338 039 | −1,93 | 19,46 | −129 718 | 6 577 123 | |
2013-03-22 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −13 334 | 0 | −100,00 | ||||
2013-03-22 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 13 334 | 344 706 | 4,02 | ||||
2013-03-20 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
A - Award | 65 000 | 65 000 | |||||
2013-03-20 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
A - Award | 32 500 | 32 500 | |||||
2013-03-05 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −9 838 | 331 372 | −2,88 | 21,00 | −206 598 | 6 958 812 |
2013-01-17 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −8 631 | 17 262 | −33,33 | ||||
2013-01-17 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −44 542 | 0 | −100,00 | ||||
2013-01-17 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −4 766 | 0 | −100,00 | ||||
2013-01-17 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 8 631 | 341 210 | 2,60 | 7,82 | 67 494 | 2 668 262 | |
2013-01-17 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 44 542 | 332 579 | 15,46 | 4,49 | 199 994 | 1 493 280 | |
2013-01-17 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 4 766 | 288 037 | 1,68 | 5,23 | 24 926 | 1 506 434 | |
2012-12-21 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −27 000 | 4 766 | −85,00 | ||||
2012-12-21 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 27 000 | 282 940 | 10,55 | 5,23 | 141 210 | 1 479 776 | |
2012-12-20 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
F - Taxes | −8 142 | 255 940 | −3,08 | 20,18 | −164 306 | 5 164 869 | |
2012-12-20 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 19 500 | 264 082 | 7,97 | ||||
2012-09-04 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −1 | 24 999 | 0,00 | ||||
2012-09-04 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −10 000 | 30 000 | −25,00 | ||||
2012-09-04 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 | 244 170 | 0,00 | 2,62 | 3 | 639 725 | |
2012-09-04 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 10 000 | 244 169 | 4,27 | 3,25 | 32 500 | 793 549 | |
2012-08-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −36 843 | 0 | −100,00 | ||||
2012-08-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −36 843 | 234 169 | −13,59 | 20,00 | −736 860 | 4 683 380 |
2012-08-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 36 843 | 271 012 | 15,73 | 7,56 | 278 533 | 2 048 851 | |
2012-08-01 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −23 234 | 31 766 | −42,24 | ||||
2012-08-01 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −23 234 | 234 169 | −9,03 | 19,00 | −441 446 | 4 449 211 |
2012-08-01 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 23 234 | 257 403 | 9,92 | 5,23 | 121 514 | 1 346 218 | |
2012-05-04 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −20 000 | 0 | −100,00 | ||||
2012-05-04 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −20 000 | 233 778 | −7,88 | 17,00 | −340 000 | 3 974 226 |
2012-05-04 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 20 000 | 253 778 | 8,56 | 7,44 | 148 800 | 1 888 108 | |
2012-04-17 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −7 111 | 233 778 | −2,95 | 15,00 | −106 665 | 3 506 670 |
2012-04-17 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −31 600 | 240 889 | −11,60 | 14,83 | −468 628 | 3 572 384 |
2012-04-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −5 200 | 272 489 | −1,87 | 16,18 | −84 134 | 4 408 763 |
2012-04-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −13 000 | 26 000 | −33,33 | ||||
2012-04-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 13 000 | 277 689 | 4,91 | ||||
2012-04-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −26 061 | 264 689 | −8,96 | 16,34 | −425 876 | 4 325 415 |
2012-03-28 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −7 500 | 0 | −100,00 | ||||
2012-03-28 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −7 500 | 290 750 | −2,51 | 16,00 | −120 000 | 4 652 000 |
2012-03-28 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 7 500 | 298 250 | 2,58 | 6,39 | 47 925 | 1 905 818 | |
2012-03-26 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −15 333 | 290 750 | −5,01 | 15,41 | −236 211 | 4 479 120 |
2012-03-26 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −38 333 | 38 333 | −50,00 | ||||
2012-03-26 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 38 333 | 306 083 | 14,32 | ||||
2012-03-21 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
A - Award | 40 000 | 40 000 | |||||
2012-03-21 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
A - Award | 82 000 | 82 000 | |||||
2012-03-21 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | −36 400 | 267 750 | −11,97 | 15,02 | −546 622 | 4 020 829 | |
2012-03-21 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | 91 000 | 0 | −100,00 | ||||
2012-03-21 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | −91 000 | 304 150 | −23,03 | ||||
2012-03-19 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −8 449 | 0 | −100,00 | ||||
2012-03-19 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −6 615 | 0 | −100,00 | ||||
2012-03-19 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 8 449 | 213 150 | 4,13 | 4,19 | 35 401 | 893 098 | |
2012-03-19 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 6 615 | 204 701 | 3,34 | 4,05 | 26 791 | 829 039 | |
2012-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −16 500 | 16 500 | −50,00 | ||||
2012-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −41 551 | 8 449 | −83,10 | ||||
2012-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
M - Exercise | −18 385 | 6 615 | −73,54 | ||||
2012-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −76 436 | 119 882 | −38,93 | 15,12 | −1 155 781 | 1 812 724 |
2012-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 16 500 | 196 318 | 9,18 | 3,90 | 64 350 | 765 640 | |
2012-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 41 551 | 179 818 | 30,05 | 4,19 | 174 099 | 753 437 | |
2012-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 18 385 | 138 267 | 15,34 | 4,05 | 74 459 | 559 981 |